Treating restrictive lung disease depends entirely on what’s causing it. Unlike a single condition with a standard protocol, restrictive lung disease is a category that includes dozens of disorders, from scarring inside the lungs to obesity pressing on the chest wall to weakened breathing muscles. Some causes can be reversed, others can only be slowed. The right treatment targets the specific reason your lungs can’t fully expand.
Why the Cause Matters for Treatment
Restrictive lung disease falls into two broad groups that require very different approaches. Intrinsic causes involve damage or inflammation within the lung tissue itself. This includes conditions like idiopathic pulmonary fibrosis, sarcoidosis, and scarring from dust exposure (silicosis, asbestosis) or certain medications. Fibrosis from COVID-19 pneumonia also falls into this category.
Extrinsic causes originate outside the lungs. Neuromuscular diseases like muscular dystrophy or ALS weaken the muscles that expand the chest. Skeletal deformities like severe scoliosis physically prevent the ribcage from opening fully. Obesity, especially morbid obesity, compresses the diaphragm and restricts chest wall movement. Pleural conditions, where fluid or scarring surrounds the lungs, also block normal expansion from the outside.
A treatment that works for one group often does nothing for the other. Antifibrotic drugs that slow lung scarring won’t help someone whose restriction comes from a curved spine. Breathing support devices that help someone with weakened muscles don’t address the inflammation driving sarcoidosis. Getting the right diagnosis is the first and most important step.
Antifibrotic Drugs for Pulmonary Fibrosis
For idiopathic pulmonary fibrosis, the most common and serious form of intrinsic restrictive disease, two antifibrotic medications can slow the rate at which lung function declines. Both have been shown in clinical trials to reduce the loss of forced vital capacity (FVC), which measures how much air you can forcefully exhale. Neither reverses existing scarring, but they can meaningfully slow progression.
Pirfenidone is typically started at a lower dose and gradually increased over several weeks to a target of about 2,400 mg per day, split into three doses. Not everyone reaches that target. In one study of patients on pirfenidone, only about 21% tolerated the full recommended dose, while the rest stabilized at lower amounts due to side effects. Nintedanib is the other option and works through a different mechanism but achieves a similar slowing effect on lung function decline. Your doctor will monitor liver function during treatment with either drug.
Immunosuppression for Inflammatory Causes
When restrictive disease stems from an overactive immune system, as in sarcoidosis or autoimmune-related lung disease, the goal is to dial down inflammation before it causes permanent scarring. Corticosteroids are the standard first step. For sarcoidosis, treatment is typically started when there are persistent lung infiltrates, declining lung function, or symptoms that impair quality of life.
Long-term steroid use carries significant side effects, so steroid-sparing medications are often added or substituted. Methotrexate is the most commonly used second-line option. If that isn’t enough, other immune-suppressing drugs or biologic medications that block specific inflammatory signals can be considered as a third line of therapy. The treatment ladder moves from broader immune suppression to more targeted approaches depending on how the disease responds.
Breathing Support Devices
For people whose breathing muscles are too weak to ventilate their lungs properly, non-invasive ventilation (often called BiPAP) delivers pressurized air through a mask, typically during sleep. This is most relevant for neuromuscular diseases like muscular dystrophy, ALS, or myasthenia gravis, where the lungs themselves may be healthy but the muscles that inflate them are failing.
Doctors typically recommend starting non-invasive ventilation when carbon dioxide levels in the blood rise above 45 mmHg during the day, or when overnight oxygen monitoring shows saturation dropping below 88% for five consecutive minutes. These are signs the breathing muscles can no longer keep up, especially during sleep when respiratory drive naturally decreases. Starting ventilation support at this stage can improve sleep quality, reduce daytime fatigue, and extend the period of adequate breathing.
Supplemental Oxygen
Supplemental oxygen doesn’t treat the underlying disease, but it becomes essential when restrictive lung disease progresses to the point where blood oxygen levels are chronically low. The general threshold for prescribing long-term home oxygen is a resting oxygen level below about 60 mmHg (roughly corresponding to a pulse oximeter reading below 88-90%), or a drop below 90% during physical activity. For patients who also develop secondary pulmonary hypertension (high blood pressure in the lung arteries), guidelines recommend using supplemental oxygen for at least 15 hours a day.
Pulmonary Rehabilitation
Pulmonary rehabilitation combines supervised exercise training, breathing techniques, and education into a structured program that typically runs 12 to 24 weeks. It doesn’t change the underlying disease, but it meaningfully improves how far you can walk, how strong your breathing muscles are, and how much breathlessness limits your daily life.
In a study of 31 patients with restrictive lung disease, the six-minute walk distance improved from 390 meters at baseline to 445 meters after 12 weeks, then continued improving to 463 meters at 24 weeks. Thigh muscle strength increased substantially, and patients reported less shortness of breath on standardized questionnaires. The majority achieved clinically meaningful improvements by 24 weeks. These gains matter practically: walking farther with less breathlessness translates directly to being able to do more in daily life.
Weight Loss for Obesity-Related Restriction
Obesity is one of the few causes of restrictive lung disease that can be fully reversed. Excess weight, particularly around the abdomen and chest, physically compresses the diaphragm and limits how much the lungs can expand. In its most severe form, this leads to obesity hypoventilation syndrome, where carbon dioxide builds up in the blood because breathing is too shallow.
The American Thoracic Society recommends sustained weight loss of 25% to 30% of total body weight to resolve or meaningfully reduce the breathing impairment from obesity hypoventilation syndrome. For someone weighing 300 pounds, that means losing 75 to 90 pounds and keeping it off. Bariatric surgery is often the most reliable path to that degree of weight loss, though any sustained approach that reaches that threshold can work. While working toward weight loss, non-invasive ventilation during sleep is typically used to manage the breathing problem in the interim.
Surgery for Chest Wall Deformities
Severe scoliosis can compress the lungs enough to cause serious restrictive disease. Spinal surgery to correct the curvature is considered when lung function is severely compromised, generally when FVC drops below 40% of the predicted value. In published surgical series, patients undergoing correction had preoperative spinal curves averaging 70 to 88 degrees. These are significant deformities, and the decision to operate involves weighing surgical risk against the progressive breathing impairment that comes with leaving the spine uncorrected. A multidisciplinary team including pulmonologists, surgeons, and anesthesiologists typically coordinates care.
Managing Pulmonary Hypertension
As restrictive lung disease progresses, chronically low oxygen levels can cause the blood vessels in the lungs to constrict and thicken, leading to pulmonary hypertension. This puts strain on the right side of the heart and worsens symptoms significantly. Unfortunately, the medications that work well for other forms of pulmonary hypertension have not shown benefit here, and some are actually harmful. Ambrisentan is contraindicated in pulmonary fibrosis-related pulmonary hypertension, and riociguat is contraindicated in interstitial lung disease-related pulmonary hypertension.
The current approach focuses on optimizing treatment of the underlying lung disease, ensuring adequate oxygen supplementation, and using diuretics to manage fluid overload if the right side of the heart starts to fail. Inhaled treprostinil has shown some promise specifically for interstitial lung disease with pulmonary hypertension, but long-term data is still limited.
Lung Transplantation
For advanced restrictive lung disease that no longer responds to medical therapy, lung transplantation remains the only option that can restore lung function. It is most commonly considered for idiopathic pulmonary fibrosis, which tends to progress relentlessly despite antifibrotic treatment. Referral for transplant evaluation typically happens when lung function is declining despite optimal therapy, oxygen requirements are increasing, or the disease is expected to be fatal within a few years.
Overall one-year survival after lung transplant was 88.5% for recipients in 2022, and five-year survival was about 60% for recipients in 2018. Patients transplanted for restrictive diseases fall in the range of roughly 58% to 62% five-year survival. These numbers represent a real extension of life for people who would otherwise face a much shorter timeline, but transplantation comes with lifelong immunosuppression and the ongoing risk of organ rejection.